Search results for "CA15-3"

showing 10 items of 21 documents

Coordinates in the Universe of Node-Negative Breast Cancer Revisited

2009

Abstract We present a global picture of the natural history of node-negative breast cancer in which two of three important biological processes have outstanding prognostic consequences. We propose that the transition from slow to fast proliferation of the tumor leads to the most dramatic aggravation of prognosis. Second, immune cell infiltration is of major importance to prevent disease progression in fast-proliferating breast carcinomas, regardless of estrogen receptor status. In the absence of endocrine treatment, steroid hormone receptor expression as a third axis is of limited prognostic importance. Dissecting tumors according to these three major biological axes will allow further unde…

CA15-3Cancer ResearchPathologymedicine.medical_specialtySteroid hormone receptorbusiness.industryCancerBreast Neoplasmsmedicine.diseaseBreast cancerOncologyTumor progressionLymphatic MetastasismedicineCancer researchHumansEndocrine systemFemaleLymph NodesBreast diseasebusinessEstrogen Receptor StatusCancer Research
researchProduct

Hsp60 and Hsp10 overexpression in metastatic colon cancer.

2006

CA15-3Hepatologybusiness.industryGastroenterologyCancer researchMedicineHSP60businessMetastatic colon cancer
researchProduct

Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.

2007

Abstract The clinical significance of serum cathepsin K and cystatin C was assessed in patients with breast cancer (BCa) or prostate cancer (PCa) with confined disease (M0) or bone metastasis (BM). Cathepsin K and cystatin C circulating levels were determined by ELISAs in 63 cancer patients, in 35 patients with nonmalignant diseases and in 42 healthy blood donors (control group). In BCa patients, cathepsin K serum levels were significantly lower than in sex matched control group (HS; p  = 0.0008) or in patients with primary osteoporosis (OP; p  = 0.0009). On the contrary, cystatin C levels were significantly higher in BCa patients than in HS ( p  = 0.0001) or OP ( p  = 0.017). In PCa patien…

CA15-3Malemedicine.medical_specialtyCathepsin KProstatic HyperplasiaBone NeoplasmsBreast NeoplasmsEnzyme-Linked Immunosorbent Assayurologic and male genital diseasesZoledronic AcidProstate cancerInternal medicinemedicineCathepsin KBiomarkers TumorHumansCystatin CAgedPharmacologyAged 80 and overbiologyBone Density Conservation AgentsDiphosphonatesbusiness.industryBone cancerImidazolesCancerBone metastasisProstatic NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseCathepsinsCystatinsBone metastasis; cathepsin K; Cystatin CEndocrinologyZoledronic acidCystatin CROC CurveBone metastasiCase-Control Studiesbiology.proteinDisease ProgressionOsteoporosisFemaleDrug Monitoringbusinessmedicine.drugBiomedicinepharmacotherapy = Biomedecinepharmacotherapie
researchProduct

Prediction of late metastasis in node-negative breast cancer.

2012

10551 Background: Prediction of late metastasis is of clinical relevance in breast cancer. However, systematic genome-wide studies to identify genes associated with increased risk of metastasis 5 or more years after surgery are scarce. Methods: We examined the natural course of disease in three previously published cohorts (Mainz, Rotterdam, Transbig) including 766 node-negative breast cancer patients with gene array data who did not receive systemic chemotherapy in the adjuvant setting. We established a Cox regression based method adjusted for multiple testing that identified genes predicting late metastasis (5 or more years after surgery). Only those genes were accepted that showed simil…

CA15-3OncologyCancer Researchmedicine.medical_specialtybusiness.industryCancermedicine.diseaseMetastasisNode negativeBreast cancerIncreased riskOncologyInternal medicinemedicineClinical significancebusinessJournal of Clinical Oncology
researchProduct

Proteomic profiling of 13 paired ductal infiltrating breast carcinomas and non-tumoral adjacent counterparts.

2006

According to recent statistics, breast cancer remains one of the leading causes of death among women in Western countries. Breast cancer is a complex and heterogeneous disease, presently classified into several subtypes according to their cellular origin. Among breast cancer histotypes, infiltrating ductal carcinoma represents the most common and potentially aggressive form. Despite the current progress achieved in early cancer detection and treatment, including the new generation of molecular therapies, there is still need for identification of multiparametric biomarkers capable of discriminating between cancer subtypes and predicting cancer progression for personalized therapies. One esta…

CA15-3Oncologymedicine.medical_specialtybusiness.industryProteomic ProfilingClinical BiochemistryDiseasemedicine.diseaseBREAST CANCER PROTEOMICSCellular originBreast cancerInfiltrating ductal carcinomaInternal medicinemedicineBreast carcinogenesisEarly Cancer Detectionskin and connective tissue diseasesbusiness
researchProduct

Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes

2012

BACKGROUND The aim of this study is to evaluate the impact of the different breast cancer subtypes on the tumor (18)F-FDG uptake at baseline and on its changes after the first course of neoadjuvant chemotherapy (NAC). PATIENTS AND METHODS One hundred and fifteen women with newly diagnosed, large or locally advanced breast cancer undergoing NAC were included. Estrogen receptor (ER), progesterone receptor (PR) and HER2 status were used to define three major tumor subtypes: triple negative (TN) (ER-/PR-/HER2-), luminal (ER+ and/or PR+; HER2-) and HER2 positive (HER2+). Using Fluorine-18 fluorodeoxyglucose positron emission tomography, the tumoral standard uptake value (SUV) maximal index was m…

CA15-3Oncologymedicine.medical_specialtymedicine.medical_treatmentEstrogen receptorStandardized uptake valueAntineoplastic AgentsBreast Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineMultimodal Imaging030218 nuclear medicine & medical imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciences0302 clinical medicineBreast cancerFluorodeoxyglucose F18Internal medicineProgesterone receptormedicineHumansskin and connective tissue diseasesPathologicalComputingMilieux_MISCELLANEOUSChemotherapybusiness.industryHematologyMetabolismmedicine.disease3. Good healthOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisPositron-Emission TomographyFemalebusinessTomography X-Ray Computed
researchProduct

Co-expression of CD133+/CD44+in human colon cancer and liver metastasis

2013

Although relatively good therapeutic results are achieved in non-advanced cancer, the prognosis of the advanced colon cancer still remains poor, dependent on local or distant recurrence of the disease. One of the factors responsible for recurrence is supposed to be cancer stem cells (CSCs) or tumor-initiating cells, which are a population of cancer cells with ability to perpetuate themselves through self-renewal and to generate differentiated cells, thought to be responsible for tumor recurrence. This study globally approach the possible role of tissue-derived stem cells in the initiation of colon cancer and its metastatic process in the liver. Fresh surgical specimens from colon cancer, no…

MaleCA15-3PhysiologyColorectal cancerSettore MED/06 - Oncologia MedicaClinical BiochemistryMetastasisCirculating tumor cellHermes antigen EMTREE medical terms: adultAC133 Antigencell populationcancer cellclinical articleColonic NeoplasmCD133 antigen; Hermes antigen adult; aged; article; cancer cell; cancer stem cell; cancer tissue; cell clone; cell compartmentalization; cell isolation; cell population; clinical article; colon cancer; disease association; female; human; human cell; human tissue; liver metastasis; male; phenotype; priority journal; protein expression Adult; Aged; Antigens CD; Antigens CD44; Colonic Neoplasms; Female; Glycoproteins; Humans; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Neoplastic Stem Cells; Peptides; Tumor Markers Biological [EMTREE drug terms]biologyLiver Neoplasmsarticlecell cloneMiddle AgedImmunohistochemistryAntigens CD44Hyaluronan Receptorsfemalecolon cancerpriority journalLiver NeoplasmTumor Markers BiologicalColonic NeoplasmsPeptideNeoplastic Stem Cellscancer tissueAdultEMTREE drug terms: CD133 antigencancer stem cellphenotypeprotein expression MeSH: Adultcell isolationAntigens CDCancer stem cellBiomarkers TumormedicineHumansliver metastasihumanGlycoproteinsAgedbusiness.industryhuman celldisease associationCD44CancerCell Biologymedicine.diseasehuman tissueCancer cellImmunologybiology.proteinCancer researchcell compartmentalizationNeoplastic Stem CellGlycoproteinPeptidesbusiness
researchProduct

Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research

2010

Breast cancer is a heterogeneous disease with different morphologies, molecular profiles, clinical behaviour and response to therapy. The triple negative is a particular type of breast cancer defined by absence of oestrogen and progesterone receptor expression as well as absence of ERBB2 amplification. It is characterized by its biological aggressiveness, worse prognosis and lack of a therapeutic target in contrast with hormonal receptor positive and ERBB2+ breast cancers. Given these characteristics, triple-negative breast cancer is a challenge in today's clinical practice. A new breast cancer classification emerged recently in the scientific scene based in gene expression profiles. The ne…

OncologyCA15-3medicine.medical_specialtyMicroarrayReceptor ErbB-2business.industryCancerBreast NeoplasmsGeneral MedicineDiseasemedicine.diseaseBreast cancerReceptors EstrogenOncologyInternal medicinemedicineHumansFemaleRadiology Nuclear Medicine and imagingReceptors Progesteroneskin and connective tissue diseasesBreast cancer classificationbusinessTriple-negative breast cancerEGFR inhibitorsCancer Treatment Reviews
researchProduct

By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy

2015

// Annalisa Petrelli 1,* , Rosachiara Carollo 2,* , Marilisa Cargnelutti 1 , Flora Iovino 2 , Maurizio Callari 3 , Daniela Cimino 4 , Matilde Todaro 2 , Laura Rosa Mangiapane 2 , Alessandro Giammona 2 , Adriana Cordova 2 , Filippo Montemurro 1 , Daniela Taverna 4 , Maria Grazia Daidone 3 , Giorgio Stassi 2,* and Silvia Giordano 1,* 1 University of Torino School of Medicine, Candiolo Cancer Institute-FPO, IRCCS, Str. Provinciale, Candiolo, Torino, Italy 2 Department of Surgical and Oncological Sciences, Cellular and Molecular Pathophysiology Laboratory, University of Palermo, Palermo, Italy 3 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy 4 Molecular Biotechnology Center (MBC),…

OncologyCA15-3medicine.medical_specialtyPathologyBreast cancer basal-like differentiation miR-100CancerEstrogen receptordifferentiationBiologybreast cancer; Basal-like; differentiation; mir-100medicine.diseasebasal-likemiR-100TransplantationBreast cancerBreast cancerOncologyInternal medicinemedicineHormonal therapyStem cellTamoxifenmedicine.drugResearch Paper
researchProduct

Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility

2017

The importance of the immune system as a potent anti-tumor defense has been consolidated in recent times, and novel immune-related therapies are today demonstrating a strong clinical benefit in the setting of several solid neoplasms. Tumor-infiltrating lymphocytes reflect the attempt of the host to eradicate malignancies, and during the last decades, they have been shown to possess an interesting prognostic utility for breast cancer, especially in case of HER2 positive and triple-negative molecular subtypes. In parallel, the clinical evaluation of tumor-infiltrating lymphocytes has been shown to effectively predict treatment outcomes in both neoadjuvant and adjuvant settings. Currently, tu…

Tumor-infiltrating lymphocytes; breast cancer; cancer immunotherapy0301 basic medicineOncologyCA15-3medicine.medical_specialtymedicine.medical_treatmentCA 15-3Tumor-infiltrating lymphocyteBreast NeoplasmsTumor-infiltrating lymphocytes03 medical and health sciencesLymphocytes Tumor-Infiltratingbreast cancer0302 clinical medicineImmune systemBreast cancerCancer immunotherapyInternal medicinemedicineHumansRC254-282cancer immunotherapyTumor-infiltrating lymphocytesbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerGeneral MedicinePrognosismedicine.diseaseNeoadjuvant TherapyTreatment Outcome030104 developmental biologyImmunoediting030220 oncology & carcinogenesisFemalebusinessTumor Biology
researchProduct